HEADER HYDROLASE 12-NOV-08 2W3K TITLE CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED TITLE 2 PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR X, HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: HEAVY CHAIN, RESIDUES 235-468; COMPND 5 SYNONYM: ACTIVATED FACTOR XA, STUART FACTOR, STUART-PROWER FACTOR; COMPND 6 EC: 3.4.21.6; COMPND 7 ENGINEERED: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: COAGULATION FACTOR X, LIGHT CHAIN; COMPND 10 CHAIN: B; COMPND 11 FRAGMENT: LIGHT CHAIN, RESIDUES 128-178; COMPND 12 SYNONYM: ACTIVATED FACTOR XA, STUART FACTOR, STUART-PROWER FACTOR; COMPND 13 EC: 3.4.21.6; COMPND 14 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS DRUG DESIGN, GLYCOPROTEIN, HYDROXYLATION, BLOOD CLOTTING, SERINE KEYWDS 2 PROTEASE, EGF-LIKE DOMAIN, FXA COAGULATION FACTOR INHIBITOR, KEYWDS 3 ZYMOGEN, PROTEASE, SECRETED, HYDROLASE, BLOOD COAGULATION, GAMMA- KEYWDS 4 CARBOXYGLUTAMIC ACID, CLEAVAGE ON PAIR OF BASIC RESIDUES EXPDTA X-RAY DIFFRACTION AUTHOR E.ZHANG,I.MOCHALKIN,A.CASIMIRO-GARCIA,C.A.VAN HUIS REVDAT 4 13-DEC-23 2W3K 1 REMARK LINK REVDAT 3 28-SEP-11 2W3K 1 REMARK HET LINK HETATM REVDAT 2 13-JUL-11 2W3K 1 VERSN REVDAT 1 07-APR-09 2W3K 0 JRNL AUTH C.A.VAN HUIS,A.CASIMIRO-GARCIA,C.F.BIGGE,W.L.CODY, JRNL AUTH 2 D.A.DUDLEY,K.J.FILIPSKI,R.J.HEEMSTRA,J.T.KOHRT, JRNL AUTH 3 R.J.J.LEADLEY,L.S.NARASIMHAN,T.MCCLANAHAN,I.MOCHALKIN, JRNL AUTH 4 M.PAMMENT,J.T.PETERSON,V.SAHASRABUDHE,R.P.SCHAUM,J.J.EDMUNDS JRNL TITL EXPLORATION OF 4,4-DISUBSTITUTED JRNL TITL 2 PYRROLIDINE-1,2-DICARBOXAMIDES AS POTENT, ORALLY ACTIVE JRNL TITL 3 FACTOR XA INHIBITORS WITH EXTENDED DURATION OF ACTION. JRNL REF BIOORG.MED.CHEM. V. 17 2501 2009 JRNL REFN ISSN 0968-0896 JRNL PMID 19231206 JRNL DOI 10.1016/J.BMC.2009.01.063 REMARK 2 REMARK 2 RESOLUTION. 2.05 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.05 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 96.6 REMARK 3 NUMBER OF REFLECTIONS : 18924 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.211 REMARK 3 R VALUE (WORKING SET) : 0.208 REMARK 3 FREE R VALUE : 0.255 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT : 1032 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.05 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.11 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1220 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 86.15 REMARK 3 BIN R VALUE (WORKING SET) : 0.2460 REMARK 3 BIN FREE R VALUE SET COUNT : 80 REMARK 3 BIN FREE R VALUE : 0.2880 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2225 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 40 REMARK 3 SOLVENT ATOMS : 121 REMARK 3 REMARK 3 B VALUES. REMARK 3 B VALUE TYPE : LIKELY RESIDUAL REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.22 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.02000 REMARK 3 B22 (A**2) : -1.83000 REMARK 3 B33 (A**2) : 1.86000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.222 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.191 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.131 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 9.107 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.947 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.930 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2317 ; 0.008 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 1598 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3129 ; 1.205 ; 1.966 REMARK 3 BOND ANGLES OTHERS (DEGREES): 3852 ; 0.819 ; 3.008 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 279 ; 6.051 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 107 ;33.880 ;24.112 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 395 ;15.638 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 15 ;21.327 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 333 ; 0.072 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2578 ; 0.003 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 473 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 448 ; 0.211 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 1650 ; 0.188 ; 0.200 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1114 ; 0.177 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): 1253 ; 0.083 ; 0.200 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 134 ; 0.127 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 9 ; 0.251 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): 23 ; 0.282 ; 0.200 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 7 ; 0.107 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1453 ; 0.586 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2248 ; 0.971 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1004 ; 1.219 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 881 ; 1.888 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 16 A 244 REMARK 3 ORIGIN FOR THE GROUP (A): -18.4937 -13.7725 23.6976 REMARK 3 T TENSOR REMARK 3 T11: -0.0922 T22: -0.0668 REMARK 3 T33: -0.0361 T12: 0.0027 REMARK 3 T13: -0.0038 T23: 0.0216 REMARK 3 L TENSOR REMARK 3 L11: 1.3758 L22: 3.0145 REMARK 3 L33: 1.5353 L12: 0.0604 REMARK 3 L13: 0.2994 L23: -0.4687 REMARK 3 S TENSOR REMARK 3 S11: -0.0443 S12: 0.0573 S13: 0.0569 REMARK 3 S21: -0.0159 S22: -0.0209 S23: -0.3927 REMARK 3 S31: -0.0005 S32: 0.0939 S33: 0.0653 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 0 B 50 REMARK 3 ORIGIN FOR THE GROUP (A): -41.5874 -13.8575 29.6383 REMARK 3 T TENSOR REMARK 3 T11: -0.0801 T22: -0.0363 REMARK 3 T33: -0.0855 T12: -0.0176 REMARK 3 T13: 0.0283 T23: 0.0561 REMARK 3 L TENSOR REMARK 3 L11: 6.5355 L22: 4.8545 REMARK 3 L33: 2.7778 L12: -2.6045 REMARK 3 L13: -2.1080 L23: 0.4294 REMARK 3 S TENSOR REMARK 3 S11: 0.1490 S12: 0.4783 S13: 0.0466 REMARK 3 S21: -0.0996 S22: 0.0137 S23: 0.3439 REMARK 3 S31: -0.0372 S32: -0.3566 S33: -0.1627 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2W3K COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 12-NOV-08. REMARK 100 THE DEPOSITION ID IS D_1290038100. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-OCT-04 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19989 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.050 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.1 REMARK 200 DATA REDUNDANCY : 5.590 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 19.3400 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.05 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.12 REMARK 200 COMPLETENESS FOR SHELL (%) : 83.0 REMARK 200 DATA REDUNDANCY IN SHELL : 4.80 REMARK 200 R MERGE FOR SHELL (I) : 0.32000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 2PHB REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.40 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.17950 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.19950 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.25150 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.19950 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.17950 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.25150 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 2070 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 16090 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -11.6 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY B 40 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 C THR B 39 O HOH B 2020 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 62 -71.20 -59.64 REMARK 500 GLN B 10 -115.46 -126.94 REMARK 500 LYS B 34 -52.27 -129.71 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A 901 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 70 OD1 REMARK 620 2 ASN A 72 O 82.9 REMARK 620 3 GLN A 75 O 164.2 87.7 REMARK 620 4 GLU A 80 OE1 97.3 174.4 93.4 REMARK 620 5 HOH A2019 O 75.2 93.7 118.2 80.9 REMARK 620 6 HOH A2021 O 73.6 81.2 92.5 104.2 148.8 REMARK 620 N 1 2 3 4 5 REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 6-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 7-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE L1D A 1245 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1WU1 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 4 -[(5-CHLOROINDOL-2-YL) REMARK 900 SULFONYL]-2-(2- METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN -2-YL] REMARK 900 CARBONYL]PIPERAZINE REMARK 900 RELATED ID: 2J34 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 REMARK 900 RELATED ID: 2VWO RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1NFW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR209685 REMARK 900 RELATED ID: 1XKA RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 2VVV RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2GD4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA- REMARK 900 PENTASACCHARIDE COMPLEX REMARK 900 RELATED ID: 1LPG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79. REMARK 900 RELATED ID: 1MSX RELATED DB: PDB REMARK 900 HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N- AMINO-15N-IMINO-13C- REMARK 900 METHYL)PHENOXY]-6-[3 -(15N-AMINO-13C-METHYL)PHENOXY]-3,5- DIFLUORO- REMARK 900 4-METHYLPYRIDINE (ZK-806299), BINDING MODELFROM DOUBLE REDOR NMR REMARK 900 AND MD SIMULATIONS. REMARK 900 RELATED ID: 2VVU RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1P0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEXWITH REMARK 900 ECOTIN M84R REMARK 900 RELATED ID: 2G00 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 3 -(6-(2'-((DIMETHYLAMINO) REMARK 900 METHYL)-4-BIPHENYLYL )-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7- REMARK 900 TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1- YL)BENZAMIDE REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(5-CHLORO-2- REMARK 900 PYRIDINYL)AMINO]CARBONYL ]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- REMARK 900 OXAZOLYL)METHYLAMINO]METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH REMARK 900 HUMAN FACTOR XA REMARK 900 RELATED ID: 1XKB RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1IQE RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55590 REMARK 900 RELATED ID: 1G2M RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2VH0 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS:BIARYL REMARK 900 PYRROLIDIN-2- ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS REMARK 900 RELATED ID: 1NFY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR200095 REMARK 900 RELATED ID: 2UWL RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 2BOK RELATED DB: PDB REMARK 900 FACTOR XA - CATION REMARK 900 RELATED ID: 1LPZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41. REMARK 900 RELATED ID: 1HCG RELATED DB: PDB REMARK 900 BLOOD COAGULATION FACTOR XA REMARK 900 RELATED ID: 1Z6E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO RAZAXABAN REMARK 900 RELATED ID: 2JKH RELATED DB: PDB REMARK 900 FACTOR XA - CATION INHIBITOR COMPLEX REMARK 900 RELATED ID: 2UWP RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1G2L RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR132747 REMARK 900 RELATED ID: 2BQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 REMARK 900 RELATED ID: 1FAX RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQF RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55165 REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/ FACTOR VIIA/FACTORXA COMPLEX REMARK 900 RELATED ID: 1IQG RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55159 REMARK 900 RELATED ID: 1IQH RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55143 REMARK 900 RELATED ID: 1LQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45. REMARK 900 RELATED ID: 2UWO RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 1C5M RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, REMARK 900 SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR REMARK 900 RELATED ID: 1IOE RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55532 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208707 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208815 REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(4-CHLOROPHENYL) REMARK 900 AMINO]CARBONYL]PHENYL]- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR XA REMARK 900 RELATED ID: 2BMG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 REMARK 900 RELATED ID: 1IQN RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55192 REMARK 900 RELATED ID: 2BQW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 REMARK 900 RELATED ID: 1IQM RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54471 REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR128515 REMARK 900 RELATED ID: 2VWL RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2VH6 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031)COMPLEXED REMARK 900 WITH FACTOR XA REMARK 900 RELATED ID: 1LPK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125. REMARK 900 RELATED ID: 2J4I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR208944 REMARK 900 RELATED ID: 2VWN RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1IQJ RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55124 REMARK 900 RELATED ID: 2J94 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2CJI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J95 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J38 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 1 REMARK 900 RELATED ID: 2W26 RELATED DB: PDB REMARK 900 FATOR XA IN COMPLEX WITH BAY59-7939 REMARK 900 RELATED ID: 2VVC RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1IQI RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55125 REMARK 900 RELATED ID: 2VWM RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1KYE RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH (R)-2-(3- ADAMANTAN-1-YL-UREIDO)-3-(3- REMARK 900 CARBAMIMIDOYL- PHENYL)-N-PHENETHYL-PROPIONAMIDE REMARK 900 RELATED ID: 1IQK RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55113 REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -[6-METHYL-4,5,6,7- REMARK 900 TETRAHYDROTHIAZOLO(5, 4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4 -(6- REMARK 900 CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE REMARK 900 RELATED ID: 2FZZ RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -(3-AMINO-1,2- REMARK 900 BENZISOXAZOL-5-YL)-6-(2 '-(((3R)-3-HYDROXY-1-PYRROLIDINYL)METHYL)-4 REMARK 900 -BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6- TETRAHYDRO-7H-PYRAZOLO[3, REMARK 900 4-C]PYRIDIN-7- ONE REMARK 900 RELATED ID: 2J2U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQL RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54476 REMARK 900 RELATED ID: 1KSN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 FXV673 REMARK 900 RELATED ID: 2W3I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4 ,4-DISUBSTITUTED REMARK 900 PYRROLIDINE-1,2- DICARBOXAMIDE INHIBITOR 2 DBREF 2W3K A 16 244 UNP P00742 FA10_HUMAN 235 468 DBREF 2W3K B 0 50 UNP P00742 FA10_HUMAN 128 178 SEQRES 1 A 234 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 234 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 234 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 234 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 234 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 234 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 234 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 234 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 234 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 234 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 234 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 234 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 234 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 234 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 234 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 234 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 234 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 234 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 1 B 51 LEU CYS SER LEU ASP ASN GLY ASP CYS ASP GLN PHE CYS SEQRES 2 B 51 HIS GLU GLU GLN ASN SER VAL VAL CYS SER CYS ALA ARG SEQRES 3 B 51 GLY TYR THR LEU ALA ASP ASN GLY LYS ALA CYS ILE PRO SEQRES 4 B 51 THR GLY PRO TYR PRO CYS GLY LYS GLN THR LEU GLU HET L1D A1245 39 HET CA A 901 1 HETNAM L1D (2R,4S)-N^1^-(4-CHLOROPHENYL)-N^2^-[2-FLUORO-4-(2- HETNAM 2 L1D OXOPYRIDIN-1(2H)-YL)PHENYL]-4-HYDROXY-4- HETNAM 3 L1D PHENYLPYRROLIDINE-1,2-DICARBOXAMIDE HETNAM CA CALCIUM ION FORMUL 3 L1D C29 H24 CL F N4 O4 FORMUL 4 CA CA 2+ FORMUL 5 HOH *121(H2 O) HELIX 1 1 ALA A 55 GLN A 61 5 7 HELIX 2 2 GLU A 124A LEU A 131A 1 9 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 LYS A 243 1 10 HELIX 5 5 LEU B 3 CYS B 8 5 6 SHEET 1 AA 7 GLN A 20 GLU A 21 0 SHEET 2 AA 7 LYS A 156 PRO A 161 -1 O MET A 157 N GLN A 20 SHEET 3 AA 7 THR A 135 GLY A 140 -1 O GLY A 136 N VAL A 160 SHEET 4 AA 7 PRO A 198 PHE A 203 -1 O PRO A 198 N SER A 139 SHEET 5 AA 7 THR A 206 TRP A 215 -1 O THR A 206 N PHE A 203 SHEET 6 AA 7 GLY A 226 LYS A 230 -1 O ILE A 227 N TRP A 215 SHEET 7 AA 7 MET A 180 ALA A 183 -1 O PHE A 181 N TYR A 228 SHEET 1 AB 7 GLN A 30 ILE A 34 0 SHEET 2 AB 7 GLY A 40 ILE A 46 -1 N PHE A 41 O LEU A 33 SHEET 3 AB 7 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 4 AB 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 AB 7 ALA A 81 LYS A 90 -1 N GLU A 86 O ARG A 107 SHEET 6 AB 7 LYS A 65 VAL A 68 -1 O VAL A 66 N HIS A 83 SHEET 7 AB 7 GLN A 30 ILE A 34 -1 O LEU A 32 N ARG A 67 SHEET 1 BA 2 PHE B 11 GLU B 15 0 SHEET 2 BA 2 SER B 18 SER B 22 -1 O SER B 18 N GLU B 15 SHEET 1 BB 2 TYR B 27 LEU B 29 0 SHEET 2 BB 2 CYS B 36 PRO B 38 -1 O ILE B 37 N THR B 28 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.04 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.05 SSBOND 3 CYS A 122 CYS B 44 1555 1555 2.04 SSBOND 4 CYS A 168 CYS A 182 1555 1555 2.02 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.02 SSBOND 6 CYS B 1 CYS B 12 1555 1555 2.04 SSBOND 7 CYS B 8 CYS B 21 1555 1555 2.01 SSBOND 8 CYS B 23 CYS B 36 1555 1555 2.03 LINK OD1 ASP A 70 CA CA A 901 1555 1555 2.40 LINK O ASN A 72 CA CA A 901 1555 1555 2.34 LINK O GLN A 75 CA CA A 901 1555 1555 2.36 LINK OE1 GLU A 80 CA CA A 901 1555 1555 2.29 LINK CA CA A 901 O HOH A2019 1555 1555 2.67 LINK CA CA A 901 O HOH A2021 1555 1555 2.34 SITE 1 AC1 6 ASP A 70 ASN A 72 GLN A 75 GLU A 80 SITE 2 AC1 6 HOH A2019 HOH A2021 SITE 1 AC2 17 GLU A 97 THR A 98 TYR A 99 ARG A 143 SITE 2 AC2 17 GLU A 147 PHE A 174 ALA A 190 GLN A 192 SITE 3 AC2 17 VAL A 213 TRP A 215 GLY A 216 GLU A 217 SITE 4 AC2 17 GLY A 219 GLY A 226 ILE A 227 TYR A 228 SITE 5 AC2 17 HOH A2096 CRYST1 56.359 72.503 78.399 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017743 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013793 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012755 0.00000